News Press room Contact Vipharm Products For the patients Career Commercial offer EU funding Reporting an adverse reaction contact Login Legal Notice Adverse Action Reporting Ladies and Gentlemen, in order to provide services at the highest level, we use cookies as part of our website. Using the website without changing the cookie settings means that they will be stored on your end device. If you do not agree, please kindly change your web browser settings. Do not show this message again

News Press room Contact Vipharm Products For the patients Career Commercial offer EU funding Reporting an adverse reaction contact Login NEWS January 2015 we introduced a new product Memantine Vipharm more ... June 2013 we introduced a new product Aropilo SR more ... November 2012 we launched a new product - Zomikos (zoledronic acid) - a modern drug used in the treatment of cancerous bone metastases more ... September 2010 we launched two new products - Olpinat ( Olanzapinum ) and Bonogren ( Quetiapinum ) - atypical antipsychotics more ... January 2010 we launched a new product - Aropilo ( Ropinirolum ) more ... - modern therapy in Parkinson's disease March 2009 launched a new product - Donesyn ( Donepezilum ) more ... marzec 2009 wprowadzliśmy na rynek nowy produkt - Risperidon Vipharm (Risperidonum) więcej... - ujety w standardach atypowy lek przeciwpsychotyczny listopad 2009 wprowadziliśmy na rynek nowy produkt - Binabic (Bicalutamidum) więcej ... - lek stosowany w leczeniu raka prostaty. styczeń 2009 X jubileusz istnienia Vipharm S.A. październik 2008 wprowadziliśmy na rynek nowy produkt - Arketis (Paroxetinum) więcej ... - lek stosowany w leczeniu depresji i zaburzeń lękowych Legal Notice Adverse Action Reporting Ladies and Gentlemen, in order to provide services at the highest level, we use cookies as part of our website. Using the website without changing the cookie settings means that they will be stored on your end device. If you do not agree, please kindly change your web browser settings. Do not show this message again

News Press room Contact Vipharm Products For the patients Career Commercial offer EU funding Reporting an adverse reaction contact Login Logging into the Medpass system Some information on the Vipharm website is only available to doctors. To confirm your identity, log in to the Medpass system. If you are an eligible person and do not have an account in the Medpass system yet, please register . Legal Notice Adverse Action Reporting Ladies and Gentlemen, in order to provide services at the highest level, we use cookies as part of our website. Using the website without changing the cookie settings means that they will be stored on your end device. If you do not agree, please kindly change your web browser settings. Do not show this message again